Figure 5 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy

Figure 5 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy

<p>Systemic LOX promotes ECM remodeling following PTX chemotherapy. Bone marrow cells were flushed from Cre<sup>+/−</sup>LOX<sup>flox/flox</sup> or their control counterpart Cre<sup>−/−</sup>LOX<sup>flox/flox</sup> mice. The bone marrow cells wer...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Jozafina Haj-Shomaly (13010115) (author)
Altres autors:	Avital Vorontsova (13010106) (author), Tamar Barenholz-Cohen (15203327) (author), Oshrat Levi-Galibov (9775532) (author), Mahesh Devarasetty (2045110) (author), Michael Timaner (13010109) (author), Ziv Raviv (361914) (author), Tim J. Cooper (13010127) (author), Shay Soker (400753) (author), Peleg Hasson (14924159) (author), Daphne Weihs (15203330) (author), Ruth Scherz-Shouval (14959181) (author), Yuval Shaked (37384) (author)
Publicat:	2025
Matèries:	Cancer Tumor Biology Therapeutic Research and Development Breast Cancer Chemotherapy Progression, Invasion & Metastasis Cell adhesion and extracellular matrix
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure 1 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure 2 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure 3 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure 4 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure 6 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure 7 from T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
per: Jozafina Haj-Shomaly (13010115)
Publicat: (2025)

Figure S1 from Breast Cancer–Secreted Factors Promote Lung Metastasis by Signaling Systemically to Induce a Fibrotic Premetastatic Niche
per: Noam Cohen (17141553)
Publicat: (2025)

Figure S2 from Breast Cancer–Secreted Factors Promote Lung Metastasis by Signaling Systemically to Induce a Fibrotic Premetastatic Niche
per: Noam Cohen (17141553)
Publicat: (2025)

Figure S3 from Breast Cancer–Secreted Factors Promote Lung Metastasis by Signaling Systemically to Induce a Fibrotic Premetastatic Niche
per: Noam Cohen (17141553)
Publicat: (2025)

Concept Matrix Derived from the Systematic Literature Review on Trend Identification in Corporate Foresight
per: Jost Wiethölter (16542063)
Publicat: (2025)

Image 3_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.png
per: Domenico Sergi (435399)
Publicat: (2025)

Image 1_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.jpeg
per: Domenico Sergi (435399)
Publicat: (2025)

Image 2_Palmitic acid differently modulates extracellular vesicles and cellular fatty acid composition of SGBS adipocytes without impairing their insulin signaling.jpeg
per: Domenico Sergi (435399)
Publicat: (2025)

Table 1_Extracellular products derived from Bacillus pumilus cultured on microalgal and cyanobacterial supplemented media: potential for controlling four specific aquaculture pathogens.docx
per: Jorge García-Márquez (3981194)
Publicat: (2025)

Data Sheet 1_Extracellular products derived from Bacillus pumilus cultured on microalgal and cyanobacterial supplemented media: potential for controlling four specific aquaculture pathogens.docx
per: Jorge García-Márquez (3981194)
Publicat: (2025)

Supplementary Table 3_Clonal distribution analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Figures from GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent Manner
per: Zijing Wang (17141626)
Publicat: (2025)

Supplementary Table 10_Pro metastatic pathways identified by classification analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 1_Primer and shRNA sequences_PCR cycles_Mycoplasma testing from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 2_Predictive power of genes and signatures_Patient cohorts GEO accession number from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 6_Gene modules analysis_GO and curated pathways associated to gene modules from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 8_Genes identified by classification analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 9_Pro metastatic pathways identified by differential expression singlePT setting from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
per: Xiaohong Hong (22681698)
Publicat: (2025)

Supplementary Table 7_Genes identified by differential expression analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 4_Marker genes all and some per cluster_GO and curated pathways per cluster from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Supplementary Table 5_Marker genes all and some per cluster no cell cycle_GO and curated pathways per cluster no cell cycle from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
per: Niccolò Roda (16437288)
Publicat: (2025)

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
per: Noor Jailkhani (16015810)
Publicat: (2025)

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
per: Noor Jailkhani (16015810)
Publicat: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
per: Noor Jailkhani (16015810)
Publicat: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
per: Chong Kin Liam (15331321)
Publicat: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
per: Chong Kin Liam (15331321)
Publicat: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
per: Chong Kin Liam (15331321)
Publicat: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
per: Chong Kin Liam (15331321)
Publicat: (2025)

The accuracy score change matrix following model development.
per: Uğur Ejder (22683228)
Publicat: (2025)

Transition metal doping for improving the fluorescence response of paralytic shellfish poisoning toxins upon pre-chromatographic derivatization
per: Paulo Vale (13163899)
Publicat: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_625r8vpbujg1e143mejpu94lf6